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Available online xxxxIL-33may play a role in the vascular remodelling of hypoxic pulmonary hypertension (PH) but the precisemech-
anisms are still unclear.We hypothesized that hypoxia promotes expression of IL-33 and its receptor ST2 on vas-
cular endothelial cells, which in turn leads to dysfunction of vascular endothelial cells and smooth muscle cells
contributing to PH. Immunohistochemistry showed that immunoreactivity for IL-33 and ST2was signiﬁcantly in-
creased in lung tissue of murine model of hypoxia-induced PH (HPH) and of subjects with bronchiectasis-PH.
trans-Thoracic echocardiography showed that haemodynamic changes and right ventricular hypertrophy associ-
ated with HPH were signiﬁcantly abrogated in St2−/− compared with WT mice. Administration of IL-33 further
exacerbated these changes in the hypoxia-exposed WT mice. In vitro, hypoxia signiﬁcantly increased IL-33/ST2
expression by human pulmonary arterial endothelial cells (HPAECs), while exogenous IL-33 enhanced prolifera-
tion, adhesiveness and spontaneous angiogenesis of HPAECs. Knockdown of endogenous Il33 or St2 using siRNA
transfection signiﬁcantly suppressed these effects in both normoxic and hypoxic culture-conditions. Deletion of
the St2 gene attenuated hypoxia-induced, elevated lung expression of HIF-1α/VEGFA/VEGFR-2/ICAM-1, while
administration of exogenous VEGFA partially reversed the attenuation of the haemodynamic indices of PH. Cor-
respondingly, knockdown of the St2 or Hif1α genes almost completely abrogated IL-33-induced expression of
HIF-1α/VEGFA/VEGFR-2 by HPAECs in vitro. Further, IL-33-induced angiogenesis by HPAECs was extensively ab-
rogated by knockdown of the Hif1α/Vegfa or Vegfr2 genes. These data suggest that hypoxia induces elevated ex-
pression of IL-33/ST2 byHPAECswhich, at least partly by increasing downstream expression of HIF-1α and VEGF
initiates vascular remodelling resulting in HPH.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
IL-33
Hypoxic pulmonary hypertension
Hypoxia inducible factor 1
Vascular endothelial growth factor1. Introduction
Hypoxic pulmonary hypertension (HPH) is commonly observed in
the context of chronic hypoxia caused by a variety of lung diseases [1,
2]. Although the precisemechanisms of HPH are largely unknown, hyp-
oxia enhanced pulmonary vasoconstriction and vascular remodelling
are considered to be the two major pathogenic processes of HPH,
resulting in elevated pulmonary vascular resistance and consequentology, School of Basic Medical
u An Men Wai, Fengtai District,
. This is an open access article under
iates Vascular Remodelling in
2018), https://doi.org/10.101pulmonary artery pressure with eventual cardiac hypertrophy and fail-
ure. The process of vascular remodelling involves many factors includ-
ing local inﬂammation, dysfunction and abnormal proliferation of
vascular endothelial cells, smoothmuscle cells and ﬁbroblasts, although
hypoxia is regarded as the key driver [3, 4].
IL-33, amember of the IL-1 family of cytokines expressedmost prom-
inently at epithelial and endothelial surfaces, acts by binding to themem-
brane receptors ST2 and IL-1RAcP (IL-1 receptor accessory protein), in a
number of lungdiseases involvingpulmonary andpulmonary vascular re-
modelling [5–9]. It is therefore reasonable to hypothesize that IL-33 also
contributes to the vascular remodelling processes of HPH through actions
on vascular endothelial cells. In addition, vascular endothelial cell growth
factor (VEGF) is a key “end effector”molecule in the vascular remodellingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2 J. Liu et al. / EBioMedicine xxx (2018) xxx–xxxof HPH, which promotes angiogenesis by regulating the proliferation, mi-
gration and differentiation of endothelial cells [1–3]. The expression of
VEGF is in turn regulated by the “molecular switch” molecule hypoxia-
induced factor 1-alpha (HIF-1α) [10, 11]. A recent study has reported
that HIF-1αmay interact with the IL-33 promoter region, resulting in in-
duction by HIF-1α of IL-33 expression in intestinal epithelial cells [12].
Other studies have shown that IL-33 promotes VEGF production by skin
mast cells and the human keratinocyte cell line HaCaT [13, 14]. However,
possible interactions between the IL-33/ST2 andHIF-1α/VEGF axes in the
pathogenesis of HPH have not so far been addressed. We, here aimed to
explore the role of both axes in the pathogenesis of the hypoxic pulmo-
nary vascular remodelling which results in HPH.2. Methods
2.1. Pulmonary Surgical Specimens
Collection of human lung tissueswas approved by the Research Ethics
Committee of BeijingChao-yangHospital. Priorwritten, informed consent
was obtained from all patients to donate lung tissues. Surgical specimens
of lung tissue were collected from patients with bronchiectasis-induced
pulmonary hypertension (PH) (n=3) and normal donor lungs removed
following accidental death for 3 patients undergoing lung transplantation
in the Beijing Chao-Yang Hospital, Capital Medical University, Beijing,
China. Lung tissues were ﬁxed in 10% formaldehyde then embedded in
parafﬁn.2.2. Animal Models
Male C57BL/6 and BALB/c mice (8 weeks) were purchased from the
Vital River Laboratory Animal Technology Company of Beijing in China.
St2−/− mice (BALB/c background) were a kind gift from Professor
Andrew N.J. McKenzie of the Medical Research Council Laboratory of
Molecular Biology, Cambridge, United Kingdom [15]. All experiments
were undertaken with approval of the Institutional Animal Care and
Use Committee (IACUC). Mice were randomly divided into two groups
which were exposed to normal air or mixed air containing 10% oxygen
in a normobaric chamber (BioSpherix, USA) for 4 weeks. The chamber
was partially ventilated and equipped with an external oxygen control-
ler which sensed the ambient oxygen concentration and replaced it
with nitrogen when necessary. Cages were opened for cleaning every
3 days for 30 min.2.3. Measurements of Haemodynamics in the Murine Model of HPH
Themeasurementswere performed as previously described [16, 17].
Following anaesthesia of the mice with 2% sodium pentobarbital
(50 mg/kg i.p.), right ventricular systolic pressure (RVSP), convention-
ally used as an indicator ofmean pulmonary arterial pressure, wasmea-
sured by closed-chest puncture of the right ventricle (RV) with a
transducer attached to the PowerLab system (ADInstruments,
Australia) as previously described [16]. A blood sample was then
taken by cardiac apex puncture for haematocrit analysis (Radiometer,
Denmark). Serum was stored in aliquots at −80 °C. Following
euthanisation, the murine lungs and hearts were collected and the
weights of the right ventricles (RV) and left ventricles including the
interventricular septa (LV + S) measured separately to evaluate the
right ventricular hypertrophy index (RVHI), which reﬂects right
ventricular remodelling, as calculated by the formula: RVHI (%) =
RV/(LV + S) × 100. The ratio of RV weight to body weight was calcu-
lated as RV/Body weight [16]. The diameters of individual
cardiomyocytes in histological sections of the left and right ventricular
walls were measured as previously described [17].Please cite this article as: Liu J, et al, IL-33 Initiates Vascular Remodelling in
Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.1012.4. Analysis of Lung Morphometrics in the Murine Model of HPH
The left lungs of the mice were embedded in parafﬁn, serially sec-
tioned at a thickness of 4 μm then stained using haematoxylin and eosin
(H&E) and immunostaining.With the aid of the H&E stain, all pulmonary
vessels with external diameters b100 μm in entire left lung were selected
and the medial thickness of these vessels quantiﬁed by immunoﬂuores-
cent labelling with anti-α-SMA (1:200 dilution, Sigma-Aldrich, USA),
visualised with second layer Fluor (AF) 488-labelled goat anti-mouse
IgG (ZsBio, China). Medial thickness was calculated as a percentage of
the external diameter of the vessels as follows: percentage medial thick-
ness (%MT) = (external diameter − internal diameter)/external
diameter × 100 [17]. The data were segregated into four groups based
on the external diameters of the vessels: 0–25, 26–50, 51–75 and
76–100 μm. Images of pulmonary vesselswere capturedwith aNikonmi-
croscope digital camera system and circumferences measured using its
image analysis software as previously described [17].
2.5. Immunohistochemical Analysis
Immunoreactivity for IL-33 and ST2 was measured using a rabbit
anti-IL-33 monoclonal antibody (1/200, Santa Cruz, CA) or rabbit anti-
ST2 monoclonal antibody (1/200, Abcam, UK) and analyzed as de-
scribed previously [16].
2.6. Cell Culture and Proliferation Assay
Human pulmonary arterial endothelial cells (HPAECs) and human
pulmonary arterial smoothmuscle cells (HPASMCs) (ScienCell Research
Laboratories, USA) were cultured according to the instruction of the
manufactures. Human pulmonary arterial endothelial cells (HPAECs)
(3–6 passages, ScienCell Research Laboratories, USA) were cultured in
complete Endothelial Cell Medium (ECM). Cells were maintained in a
CO2 incubator (5%, Thermo, USA) at 37 °C and used for experiments at
80%–90% conﬂuence. After starvation by culture in ECM containing 2%
foetal bovine serum (FBS) to arrest growth for 4–6 h, cells were pre-
treated with either human recombinant IL-33 (rhIL-33) (10 ng/mL,
R&D systems, MN, USA) or vehicle (PBS) in 5% FBS-ECM, followed by
stimulation under conditions of hypoxia (3% oxygen) or normoxia
(21% oxygen) for a further 24 h. Human pulmonary arterial smooth
muscle cells (HPASMCs) (4–8 passages, ScienCell Research Laborato-
ries) were cultured in complete smooth muscle cell medium (SMCM).
Cells were maintained in a CO2 incubator (5%, Thermo, USA) at 37°C
and used for experiments at 80%–90% conﬂuence.
Proliferation of HPAECs was assayed using a bromodeoxyuridine
(BrdU) ﬂow kit purchased from BD Pharmingen (BD Pharmingen, USA)
according to themanufacturer's instructions. Brieﬂy,HPAECswere seeded
at 5×105cells per culture bottle and cultured for 24hunder different con-
ditions. For analysis of DNA synthesis, cells were incubatedwith BrdU (10
μM) at 37 °C for 1 h. After collection, cells were treated with
cytopermeabilisation/ﬁxation medium (BD) then exposed to DNase
(300 μg/mL dissolved in Dulbecco's Phosphate Buffered Saline, D-PBS)
at 37 °C for a further 1 h. The incorporated BrdUwas stainedwith speciﬁc
anti-BrdUﬂuorescent antibody at room temperature for 20min. A dye (7-
aminoactinomycin D, 20 μL per sample) was added for staining of total
DNA. Cells were analyzed using an LSRFortessa ﬂow cytometer (Becton
Dickinson, USA) which discriminated cells in S phase (P4), G0/G1 phase
(P3), G2 phase (P5) and cells undergoing apoptosis (P6). The percentage
of cells in S phase was calculated as P4/(P3 + P4 + P5) × 100%.
Proliferation of human pulmonary artery smooth muscle cells
(HPASMCs) was measured using a commercial kit (Cell Counting Kit-
8, Dojindo, Japan). Brieﬂy, HPASMCs were seeded at 5 × 103cells per
well in a 96-well plate, then incubated at 37 °C for 24 h before adding
rhIL-33 (R&DSystems) atﬁnal concentrations of 10ng/mLor normal sa-
line control in a total volume of 200 μL in culturemediumwithout foetal
bovine serum (FBS). Cells were cultured with platelet-derived growthHypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF
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cubation for a further 24 h, 10 μL of CCK-8 solution were added to each
well and the cells incubated for a further 4 h. The absorbance of theme-
dium at 450 nmwasmeasured with Perkin Elmer EnSpire®Multimode
Plate Reader (Waltham, MA, USA).2.7. Endothelial Cell Adhesion and Tube Formation Assays
HPAECs were incubated with different concentrations of IL-33 or
siRNAs speciﬁc for IL-33, ST2 or HIF-1α for 24 h. Cellular adhesion,
tube formation, tube lengths and numbers were quantiﬁed using
Image J and NIS-Elements BR Analysis (Nikon) [18].Fig. 1. Increased right ventricular systolic pressure (RVSP) and right ventricular hypertrophy i
from wild type mice exposed to normoxia(N4W)or to hypoxia (H4W) for 4 weeks. (A) RV
control mice (N4W) (n = 6 each group). Data are presented as the mean ± SEM. ***p b 0
(C) Western blot analysis of IL-33 and ST2 proteins (fold changes compared with β-actin) in
the references to colour in this ﬁgure legend, the reader is referred to the web version of this a
Please cite this article as: Liu J, et al, IL-33 Initiates Vascular Remodelling in
Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.1012.8. Cell Co-culture Assay
To explore whether experimentally manipulated HPAECs affect the
function of HPASMCs, we employed a non-contact, transwell co-
culture model [19]. To measure cellular proliferation, 8 × 104 HPAECs
per well were seeded into 12-well culture dishes, while HPASMCs at a
density of 3 × 104 per insert were seeded into permeable (0.4 μm
pore) transwell culture inserts (Millipore, MA, USA). HPASMCs were
starved by culture in SMCM containing 2% FBS for 24 h, then the
transwell inserts positioned into the wells of the HPAECs culture plates
to establish co-culture conditions for a further 24 h in a mixed medium
(1:1)mixture of ECM:SMCM(basic culturemedium for endothelial cells
and smooth muscle cells) with or without IL-33 (10 ng/mL). Followingndex (RVHI) and elevated expression of IL-33 and ST2 immunoreactivity in lung sections
SP and RVHI in murine models of hypoxia-induced murine PH (H4W) compared with
.001. (B) Immunoreactivity for IL-33 and ST2 (brown) in murine lung tissue sections.
lung tissue of murine models (n = 4–6 in each group). *p b 0.05. (For interpretation of
rticle.)
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Fig. 2. Elevated expression of IL-33 and ST2 in patients with PH. (A and B) Immunoreactivity for IL-33 and ST2 (brown) in lung tissues from patients with bronchiectasis with PH
and normal controls (n= 3 for each group). The arrows show pulmonary artery endothelia cells which are immunoreactive for IL-33 and ST2. Data are presented as the mean ±
SEM. **p b 0.01; *p b 0.05. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
4 J. Liu et al. / EBioMedicine xxx (2018) xxx–xxxculture, the membranes of the inserts were washed with PBS twice,
ﬁxed in 4% paraformaldehyde for 30min, then removed and the cellular
nuclei stained with DAPI. The numbers of HPASMCs on the upper sur-
faces of themembranes were counted under high-power magniﬁcation
using a microscope digital camera (Nikon, Japan). To measure cellular
migration, HPAECs (1 × 105cells/well) were seeded into 12-well culture
dishes, while arrested HPASMCs (1 × 105cells/per insert) were seeded
into permeable (8 μm pore) transwell culture inserts which were then
positioned into the wells of the HPAECs culture plates. After 24 h, the
upper surfaces of the membrane inserts were washed with PBS twice
and swabbedwith a cotton bud to remove non-migrated cells. Migrated
cells on the lower surface of the membrane were ﬁxed in 4%Fig. 3.Deletion of the St2 gene reversed hypoxia-induced PHwhile IL-33 aggravated hypoxic pu
type and St2−/− mice under conditions of normoxia and hypoxia: (top left panel) H&E stain
showing pulmonary arterioles; (right) Percentage medial thicknesses (%MT) of pulmonary art
and 76–100 μm). ***p b 0.001 (vs N4W-WT: WT mice exposed to normoxia for 4 weeks); ##
arterioles in the entire left lung sections, n = 6 mice in each category). (B) Sections of
Cardiomyocyte hypertrophy was evident in the right ventricle (left panel), but not the left v
mice under hypoxia) (data show mean ± SEM of the diameter of 200 cardiomyocytes per sec
and St2−/− mice exposed to normoxia compared to hypoxia. *** p b 0.001 (vs wild type mice
6–10 each group). (D) Administration of IL-33 aggravated hypoxic pulmonary vascular remod
IL-33. (middle panel) H&E staining of pulmonary arterioles from mice under hypoxia with or
hypoxia with or without exogenous IL-33 grouped by external diameter (mean ± SEM of all ar
Please cite this article as: Liu J, et al, IL-33 Initiates Vascular Remodelling in
Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.101paraformaldehyde for 30 min, then their nuclei stained with DAPI and
counted as described above.
2.9. Cellular Transfection with Small Interfering RNA (siRNA) Species
HPAECs were transiently transfected with siRNA species in Opti-
MEMmedium (Invitrogen, Carlsbad, CA) using LipofectamineRNAiMAX
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
The efﬁciency of siRNA transfectionwasmeasured by qRT-PCR orWest-
ern blot analysis. The sequences of siRNA used in the experiments were
as follows:
(IL-33): sense: 5′-GCU CUG GCC UUA UGA UAA ATT-3′; and.lmonary vascular remodelling. (A) Comparison of pulmonary vascular remodelling inwild
ing of pulmonary arterioles; (bottom left panel) Immunoﬂuorescent staining of α-SMA
erioles categorised by external diameter into four groups (0–25 μm, 26–50 μm, 51–75 μm
#p b 0.001 (vs H4W-WT: WT mice exposed to hypoxia for 4 weeks) (mean ± SEM of all
cardiomyocytes from wild type and St2−/− mice exposed to normoxia and hypoxia.
entricle (right panel). ***p b 0.001 (vs WT mice under normoxia), ###p b 0.001 (vs WT
tion, n= 6mice in each category). (C) RVSP, RVHI and RV/body weight ratio of wild type
under normoxia), ###p b 0.001 (vs wild type mice under hypoxia) (mean ± SEM, n =
elling. (left panel) RVSP and RVHI of wild type mice exposed to hypoxia with or without
without exogenous IL-33. (right panel) %MT of pulmonary arterioles of mice exposed to
terioles in the entire left lung sections, n= 6mice in each group). ***p b 0.001, **p b 0.01.
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Fig. 4. Effects of exogenous IL-33 or of depletion of ST2 on RV wall thickness and the peak velocity of blood ﬂow. IL-33 aggravates hypoxic pulmonary vascular remodelling. Magnetic
resonance imaging (MRI) and M-mode trans-thoracic echocardiography showing typical cross sectional images of the heart (A), the thickness of the RV wall (B) and the PA peak ﬂow
velocity (C) in mice exposed to normobaric hypoxia concomitantly with exogenous IL-33 or normal saline for 4 weeks. Typical images showing changes of thickness of the RV wall (D,
as indicated by arrow) and PA peak velocity (E) in WT and St2−/−mice exposed to normoxia or hypoxia. The results were measured by M-mode trans-thoracic echocardiography.
Fig. 5. Effects of exposure to hypoxia on expression of IL-33 by human pulmonary arterial endothelial cells (HPAECs) and effects of exogenous IL-33 on HPAECs. (A) Hypoxia-induced
expression of IL-33 mRNA (left) and protein (right) by HPAECs (n = 4). *p b 0.05, **p b 0.01. (B) Effects of IL-33 on the cell cycle positions and DNA synthetic activities of HPAECs
determined by analysing total DNA and incorporated BrdU using ﬂow cytometry. The cells were treated with or without IL-33 for 24 h under normoxia. Gate P3 represents cells in G0/
G1 phase, P4 is S phase, P5 is G2 + M phase, and P6 is apoptotic cells. *p b 0.05, n = 3. (C) (left panel) Adhesion of HPAECs to culture plate wells in the presence of various
concentrations of IL-33 under conditions of normoxia or hypoxia. Adherent cells were counted and expressed as the numbers of cells per high power ﬁeld (5 wells for each group, and
6 HPFs in each well were counted). ***p b 0.001, ###p b 0.001. (right panel) Adhesion of HPAECs following IL-33 gene knock down by siRNA under conditions of normoxia or hypoxia
(n = 5). **p b 0.01, ***p b 0.001. (D) (left panel) Spontaneous formation of capillaries (angiogenesis) by HPAECs cultured with IL-33 at various concentrations under conditions of
normoxia or hypoxia. (right panel) Angiogenesis by HPAECs following IL-33 knock down by siRNA under conditions of normoxia or hypoxia. The results are expressed as the mean
total tube lengths (percentages of medium control values) and numbers of tubes per ﬁeld, respectively (n= 6). **p b 0.01, ***p b 0.001, ###p b 0.001.
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8 J. Liu et al. / EBioMedicine xxx (2018) xxx–xxxanti-sense: 5′-UUU AUC AUA AGG CCA GAG CTT-3′.
(ST2): sense: 5′-GCG AAU GUC ACC AUA UAU ATT-3′; and.
anti-sense: 5′-UAU AUA UGG UGA CAU UCG CTT-3′.
(HIF-1α): sense: 5′-GGC CGC UCA AUU UAU GAA UTT-3′; and.
anti-sense: 5′-AUU CAU AAA UUG AGC GGC CTT-3′.
(VEGFA): sense: 5′-GGC AGC UUG AGU UAA ACG ATT-3′; and.
anti-sense: 5′-UCG UUU AAC UCA AGC UGC CTT-3′.
(VEGFR-2): sense: 5′-CUC GGU CAU UUA UGU CUA UTT-3′; and.
anti-sense: 5′-AUA GAC AUA AAU GAC CGA GTT-3′.
Non-speciﬁc siRNA sequences were used as negative controls:
sense: 5′-UUC UCC GAA CGU GUC ACG UTT-3′; and.
anti-sense: 5′-ACG UGA CAC GUU CGG AGA ATT-3′.
(GenePharma, Shanghai, China).2.10. qRT-PCR
Total RNA was extracted from lung tissue or cultured HPAECs using
Trizol reagents (Sigma-Aldrich, USA). Reverse transcription was per-
formed using the Superscript III First-strand Synthesis System
(Invitrogen, USA) and quantitative, real-time PCR with Power SYBR
Green PCR Master Mix (Applied Biosystems, UK) using a Mx3000P Sys-
tem (Stratagene, USA) as previously conducted in our laboratory.36 The
relative abundance of IL-33 and ST2 mRNA in HPAECs was normalised
to that of GAPDH using a comparative cycle threshold method
(2−ΔΔCT). The primer sequences were as listed below:
IL-33: sense: 5′-GGAGTGCTTTGCCTTTGGTA-3′;
anti-sense: 5′-CCATCAACACCGTCACCTG -3′.
ST2: sense: 5′-CAACTGGACAGCACCTCTTG-3′;
anti-sense: 5′-GGTGTAATCACCTGCGTCCT -3′.
GAPDH: sense: 5′-CGGAGTCAACGGATTTGGTCGTAT-3′;
anti-sense: 5′-AGCCTTCTCCATGGTGGTGAAGAC-3′.2.11. Western Blotting
Equal amounts of protein extracted from lung tissue and HPAECs
were separated by sodium dodecyl sulphate-polyacrylamide gel (SDS-
PAGE) electrophoresis then transferred to a nitrocellulose membrane
(NC, 0.45 μm, Millipore, USA). After blocking with 5% non-fat milk for
1 h at room temperature, the membrane was incubated with primary
antibodies speciﬁc for IL-33 (mouse mAb, 1:200 dilution, Abcam), β-
actin (rabbit mAb, 1:2000 dilution, Sigma-Aldrich), GAPDH (rabbit
mAb, 1:2000 dilution, Sigma-Aldrich, USA), ST2 (rabbit mAb, 1:200 di-
lution, Abcam), HIF-1α (rabbit mAb, 1:50 dilution, Abcam), VEGFA
(rabbit mAb, 1:100 dilution, Abcam), VEGFR-2 (rabbit mAb, 1:200 dilu-
tion, Cell Signalling Technology, USA) and ICAM (rat mAb, 1:200 dilu-
tion, Cell Signalling Technology) overnight at 4 °C. The membrane was
then washed in PBST (0.1% Tween 20-PBS, Sigma-Aldrich) thrice for
10 min and incubated with IRDye800-conjugated secondary antibody
(mouse or rabbit mAb, 1:10000, Odyssey LI-COR, USA) for 1 h. After
washing in PBST thrice for 10 min again, the membrane staining was
visualised using the LI-COROdyssey imaging system. Theprotein signals
were quantiﬁed using Image J and their relative expression normalised
to that of GAPDH or β-actin as house-keeping protein or as ratios of
their respective maximal expression.2.12. Statistical Analysis
All data are expressed as the mean ± standard error of the mean
(SEM) and were analyzed using GraphPad Prism 5.0 (GraphPad Soft-
ware, USA). One-way analysis of variance (ANOVA) moderated by
Tukey's Multiple Comparison correction was used to detect variation
between 3 or more groups. Comparison between two groups was con-
ducted using the two-tailed, unpaired Student's t-test. Statistical signif-
icance was deﬁned as P b 0.05.Please cite this article as: Liu J, et al, IL-33 Initiates Vascular Remodelling in
Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.1013. Results
3.1. Elevated Lung Tissue Expression of IL-33 and ST2 in A Murine Model of
HPH and Human Subjects With Bronchiectasis Complicated by PH
The mean right ventricular systolic pressure (RVSP) and right ven-
tricular hypertrophy index (RVHI), major feature of HPH,were substan-
tially elevated in mice with PH induced by exposure to a hypoxic
environment for 4 weeks (H4W) compared with control mice exposed
to normal air (N4W) (Fig. 1 A, p b 0.001, respectively). Immunoreactiv-
ity for IL-33 and ST2 was elevated in the lung sections of mice with
hypoxia-induced PH and localised principally to the airways epithelium
and pulmonary vascular endothelium (Fig. 1 B). Western blotting fur-
ther conﬁrmed that the IL-33 and ST2 protein expression was signiﬁ-
cantly increased in the murine lung tissue of the animals to hypoxia
compared with normoxia (Fig. 1 C, p b 0.05).
Immunoreactivity for IL-33 and ST2 also signiﬁcantly increased in
lung sections frompatientswith bronchiectasis complicated by PH com-
pared with normals, predominantly in the endothelial cells of the pul-
monary arterioles (Fig. 2 A and B, IL-33: p b 0.01, ST2: p b 0.05).3.2. St2−/− Mice Show Attenuated, Hypoxia-induced Pulmonary Vascular
Remodelling and Hypertrophy of Individual Cardiomyocytes of the RV and
are Resistant to the Development of Hypoxia-induced PH
H&E staining (Fig. 3 A, top panel) and immunoﬂuorescent stain-
ing of alpha-smooth muscle actin (α-SMA) (Fig. 3 A bottom panel)
showed that the mean percentage medial thickness (%MT) of the
arterioles was signiﬁcantly elevated in WT mice following expo-
sure to hypoxia, an effect which was signiﬁcantly attenuated in
the St2−/− mice, at least in vessels of diameter 75 μm or less
(Fig. 3 A, right, p b 0.001).
H&E staining showed that hypoxia resulted in a signiﬁcant elevation
of themean diameter of the cardiomyocytes in the right ventricle in the
WT mice (Fig. 3 B, bottom panel, p b 0.001), consistent with the pres-
ence of hypoxia-triggered right ventricular hypertrophy, a hallmark of
end-stage pulmonary hypertension [20], an effect almost completely
abrogated in St2−/−mice (p b 0.001). No such changes were observed
in the left ventricular cardiomyocytes in the WT or the St2−/− mice
whether exposed to normoxia or hypoxia.
Haemodynamics analysis showed that hypoxia-exposedWT, but
not St2−/− mice developed pulmonary hypertension characterised
by signiﬁcant elevation of the mean RVSP, RVHI and RV/body
weight ratio in response to chronic hypoxia as compared with the
control, normoxic group (Fig. 3 C, p b 0.001, respectively), although
there were no signiﬁcant changes in these indices in St2−/− andWT
mice exposed to normoxia (Fig. 3 C). Correspondingly, hypoxia-
exposed St2−/− mice developed a signiﬁcantly lower mean RVSP,
RVHI and RV/body weight ratio compared with the WT mice
(Fig. 3 C p b 0.001, respectively).3.3. Effects of Exogenous IL-33 on HPH
To clarify the effects of exogenous IL-33 on HPH, WT mice were
exposed to normobaric hypoxia for 4 weeks concomitantly with intra-
peritoneal injections of IL-33 or normal saline (twice weekly, rmIL-33,
1 μg/dose/mouse). Compared with the saline control, IL-33 further ag-
gravated pulmonary hypertension in mice exposed to hypoxia, as
shown by signiﬁcant elevation of the mean RVSP (p b 0.001) and RVHI
(p b 0.01) (Fig. 3 D, left panel). In addition, H&E staining showed that
IL-33 compared with saline treatment was associated with further,
signiﬁcant elevation of %MT of the pulmonary arterioles with exter-
nal diameters b75 μm (Fig. 3 D, middle and right panels, p b 0.01 and
p b 0.001, respectively).Hypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF
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9J. Liu et al. / EBioMedicine xxx (2018) xxx–xxx3.4. Effects of Exogenous IL-33 or of Depletion of ST2 on RV Wall Thickness
and the Peak Velocity of Blood Flow
Transthoracic echocardiography showed that exposure of mice to
exogenous IL-33 further increased the right ventricular (RV) wallFig. 6. IL-33 regulates the function ofHPAECs via ST2. (A) Effects of hypoxia on expression of St2m
down of ST2 expression with siRNA on hypoxia- and IL-33-induced adhesion of HPAECs (mean
0.001, ###p b 0.001. (C) Effects of knock down of ST2 expression with siRNA on hypoxia- and IL
tube lengths (percentages of medium control values) and numbers of tubes per ﬁeld, respectiv
Please cite this article as: Liu J, et al, IL-33 Initiates Vascular Remodelling in
Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.101thickness (Fig. 4 A), while transthoracic echocardiography conﬁrmed
this and also revealed further reduction of the peak velocity of blood
ﬂow in the pulmonary artery (Fig. 4 B and C). The changes were atten-
uated in the St2−/−mice compared with the WT mice following expo-
sure to hypoxia (Fig. 4 D and E).RNA(left) and protein (right) byHPAECs (n=4). *p b 0.05, **p b 0.01. (B) Effects of knock
± SEM, n= 5). The results are expressed as numbers of cells per high power ﬁeld. ***p b
-33-induced angiogenesis by HPAECs (n=6). The results are expressed as the mean total
ely. ***p b 0.001, ###p b 0.001.
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10 J. Liu et al. / EBioMedicine xxx (2018) xxx–xxx3.5. Hypoxia Induces Expression of IL-33 by HPAECs, While IL-33 Enhances
Proliferation, Adhesion and Remodelling of HPAECs In Vitro
Q-PCR analysis revealed a transient increase in IL-33 mRNA expres-
sion by cultured HPAECs as early as 1 h following exposure to hypoxiaFig. 7. Effects of co-culture with HPAECs on proliferation and migration of HPASMCs in the p
positive control PDGF promoted the proliferation of HPASMCs (n= 6 each group). ***p b 0.00
co-cultured with HPAECs (labelled EC) (n= 6 each group). ***p b 0.001, ###p b 0.001. (C) The
(labelled EC) (n= 6 each group). ***p b 0.001.
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Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.101(Fig. 5 A, left, p b 0.05), while Western blotting analysis conﬁrmed ele-
vated IL-33 protein 12 h after exposure (Fig. 5 A right, p b 0.01).
Recombinant human IL-33 (rhIL-33) in vitro signiﬁcantly enhanced
progression of the HPAECs into the S phase of cellular division, as
shown by ﬂow cytometric analysis of the cells following BrdUresence/absence of IL-33. (A) IL-33 alone did not affect proliferation of HPASMCs, while
1, ###p b 0.001. (B) The effect of IL-33 on proliferation of HPASMCs (labelled SMC) when
effect of IL-33 on migration of HPASMCs (labelled SMC) when co-cultured with HPAECs
Hypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF
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Fig. 8. Attenuated hypoxia-induced pulmonary vascular remodelling in St2−/−mice reﬂects reduced expression of HIF-1α/VEGFA/VEGFR-2. (A) Western blot analysis of HIF-1α, VEGFA,
VEGFR-2 and ICAM-1 in lung tissues ofWT and St2−/−mice following exposure to normoxia and hypoxia in vivo (n=3–7). *p b 0.05, **p b 0.01. (B) RVSP, RVHI and RV/bodyweight ratios
ofWTmice exposed to normoxia and hypoxia, and St2−/−mice exposed to hypoxiawith orwithout exogenous VEGFA (n=6–8 each group). *p b 0.05, **p b 0.01, ***p b 0.001, ##p b 0.01,
###p b 0.001. (C) Pulmonary vascular remodelling in WT mice exposed to normoxia and hypoxia, and St2−/−mice exposed to hypoxia with or without exogenous VEGFA (n= 4 each
group). (left) H&E staining of pulmonary arterioles. (right) Percentage medial thickness (%MT) of pulmonary arterioles grouped according to external diameter (μm). **p b 0.01, ***p b
0.001, ###p b 0.001.
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13J. Liu et al. / EBioMedicine xxx (2018) xxx–xxxincorporation (Fig. 5 B, p b 0.05), suggesting that IL-33 is able to increase
the proliferation of these cells even under conditions of normoxia. Fur-
thermore, under conditions of both normoxia and hypoxia, rhIL-33 sig-
niﬁcantly and concentration-dependently further enhanced HPAECs'
adhesion (Fig. 5 C left panel, p b 0.001). Knockdown of the Il33 gene
in the cells by siRNA transfection signiﬁcantly abrogated the capacity
under conditions of both normoxia and hypoxia (Fig. 5 C right panel,
p b 0.01, p b 0.001 respectively).
Finally, similar effects were observed on the ability of the HPAECs
to assemble into tubular vessels. Compared with normoxic condi-
tions, hypoxia in vitro increased the lengths and numbers of sponta-
neously formed tubules. Furthermore, rhIL-33 enhanced tubule
formation in a concentration-dependent fashion (Fig. 5 D left panel,
p b 0.001), while knockdown of the Il33 gene almost completely at-
tenuated the effects of hypoxia on this phenomenon (Fig. 5 D right
panel, p b 0.001).
3.6. The ST2 Receptor Mediates the Effects of Hypoxia and Exogenous IL-33
Exposure on HPAECs
In order to clarify the role of IL-33 receptor ST2,wemeasured the ex-
pression of ST2 mRNA and protein by HPAECs. Q-PCR analysis showed
that production of mRNA encoding ST2 was upregulated 8.05-fold at
1 h following exposure of the cells to hypoxia compared with normoxia
(Fig. 6 A left, p b 0.01). Correspondingly, western blotting showed that
ST2 proteinwas upregulated up to 1.55-fold at 12 h after hypoxia expo-
sure (Fig. 6 A right, p b 0.05). Furthermore, knockdown of the St2 gene
not only attenuated their capacity to adhere and form tubules when ex-
posed to hypoxia, but also abrogated the effects of exogenous IL-33
under conditions of both normoxia and hypoxia (Fig. 6 B and C, p b
0.001 in each case).
3.7. IL-33 Enhanced Proliferation of HPASMCs When Co-cultured With
HPAECs
In our in vitro proliferation assay, co-culture of HPAECs with
HPASMCs induced proliferation of the latter (Fig. 7 B, p b 0.001 com-
pared with SMC monoculture), an effect which was further enhanced
by rhIL-33 (p b 0.001), although IL-33 alone under these conditions
did not signiﬁcantly alter proliferation of the HPASMCs when cultured
in isolation (Fig. 7 A). In addition, co-culture of HPAECs with HPASMCs
also increased spontaneous HPASMC migration (Fig. 7 C p b 0.001), al-
though this effect was not further enhanced by rhIL-33, while IL-33
alone did not induce HPASMC migration in the absence of HPAECs.
3.8. Attenuation of Hypoxia-induced Pulmonary Vascular Remodelling in
St2−/−Mice Reﬂects Reduced Expression of HIF-1α/VEGFA/VEGFR-2
Compared with normoxia, hypoxia increased expression of HIF-1α
protein in the lung tissue of the WT mice, but not in the St2−/− mice
(Fig. 8 A, p b 0.01). In contrast, deletion of the St2 gene did not inﬂuence
HIF-1α expression inmice exposed to normoxia. Similarly, hypoxia also
increased expression of VEGFA and VEGFR-2 protein in the lung tissues
of theWT mice (Fig. 8 A, p b 0.01, p b 0.05 respectively), an effect again
completely abrogated in the St2−/−mice (Fig. 8 A p b 0.05). Again, dele-
tion of the St2 gene did not affect expression of these proteins in animals
exposed to normoxia. Finally, hypoxia was associated with elevated ex-
pression of ICAM-1 protein in the WT mice (Fig. 8 A, p b 0.05), which
was also signiﬁcantly diminished in the St2−/−mice (Fig. 8 A, p b 0.05).Fig. 9. IL-33/ST2 enhances angiogenetic activity of HPAECs through the HIF-1α/VEGFA/VEGFR
HPAECs incubated with exogenous IL-33 (10 ng/mL) or medium control following transfecti
0.01. (B) Western blot analysis of VEGFA and VEGFR-2 protein expression in HPAECs treated w
4). *p b 0.05, **p b 0.01, ***p b 0.001. (C) Angiogenetic ability of HPAECs treated with exogen
6). The results are expressed as the mean total tube lengths (percentages of control values) an
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protein for the IL33/ST2 axis in HPH, hypoxia-exposed St2−/− and WT
mice were injected intraperitoneally with recombinant mouse VEGFA
protein (rmVEGFA, R&D Systems, 100 ng/dose/mouse, twice weekly).
Again, VEGFA partially reversed the reductions in mean RVSP, RVHI
and RV/body weight ratio observed in the St2−/− compared with the
WT mice following exposure to hypoxia (Fig. 8 B, p b 0.05 and p b
0.01, respectively). Accordingly, H&E staining showed attenuated arte-
rial remodelling in the St2−/−mice comparedwith theWTmice follow-
ing exposure to hypoxia (Fig. 8 C left panel), with reduction in the %MT
of pulmonary arterioles smaller than 75 μm in diameter, administration
of exogenous VEGFA partially but signiﬁcantly reversed these changes
(Fig. 8 C right panel, p b 0.001 and p b 0.01, respectively).
In vitro, Western blotting showed that rhIL-33 treatment signiﬁ-
cantly increased expression of HIF-1α, VEGFA and VEGFR-2 protein by
HPAECs (Fig. 9 A). Prior knockdown of the St2 gene using siRNA
completely abrogated such effects of IL-33. Furthermore, prior knock-
down of the Hif1α gene completely abrogated the ability of IL-33 to in-
crease the expression of VEGFA and VEGFR-2 (Fig. 9 B). Finally, prior
knockdown of the genes encoding HIF-1α, VEGFA or VEGFR-2
completely abrogated the IL-33-induced angiogenetic activity of these
cells at 24 h in a normoxic environment (Fig. 9 C).
4. Discussion
Although IL-33 has now been implicated in the pathogenesis of
many lung inﬂammatory and remodelling processes [21–23], its possi-
ble role in the pathogenesis of HPH per se remains unclear. Our observa-
tion that the expression of IL-33 and its receptor ST2 is up regulated in
pulmonary arterial endothelial cells in sections of lung tissue obtained
frommurinemodel of HPH and frompatientswithHPH impelled us fur-
ther to explore the potential roles of IL-33/ST2/HIF-1α/VEGF signalling
pathways in the pathogenesis of this phenomenon using in vivo and
in vitro experiments.
Our data clearly support the hypothesis that exposure of the airways
to hypoxia upregulates expression of IL-33/ST2 by lung structural cells,
in particular pulmonary arterial endothelial cells, which in turn contrib-
utes to hypoxic pulmonary vascular remodelling at least partly through
activating downstream of the IL-33/ST2 axis, in particular HIF-1α/VEGF
signalling. Although it is well known that HIF-1α and VEGF are critical
mediators in the phenomenon of hypoxia-induced vascular remodel-
ling, so far as we are aware no study to date has addressed in detail
the events upstream of these molecules, and in particular whether or
not these upstream events are inﬂuenced by IL-33/ST2 signalling. In
the present study, while knockdown of the gene encoding IL-33 recep-
tor, ST2, did not alter the baseline expression of HIF-1α, VEGF and
VEGFR-2 in the lung tissue of the experimentalmice in normoxic condi-
tions, it did reduce the elevated expression of all three proteins in re-
sponse to hypoxia, suggesting that elevated production of IL-33, acting
on its receptor ST2, in the presence of sustained hypoxia is a trigger
for elevated production of HIF-1α and VEGF and the initiation of the
vascular remodelling which results in HPH. This conclusion is further
supported by our in vitro experiments in which knockdown of the ST2
gene in HPAECs abrogated the effects of exogenous IL-33 and/or hyp-
oxia in upregulating the expression of HIF-1α, VEGFA and VEGFR-2. Ad-
ditionally, exposure to IL-33 increased the proliferation, adhesiveness
and angiogenetic activity of HPAECs, an effect abrogated by knockdown
of any one of these mediators, suggesting that the end effect of activa-
tion of the IL-33/HIF-1α/VEGFA axis in these cells is to initiate and sus-
tain the vascular remodelling which eventually results in HPH. This axis-2 axis. (A) Western blot analysis of HIF-1α, VEGFA and VEGFR-2 protein expression in
on with siRNA encoding ST2 or control (n = 4–7). *p b 0.05, **p b 0.01, #p b 0.05, ##p b
ith exogenous IL-33 following transfection with siRNA encoding HIF-1α or control (n=
ous IL-33 following transfection with siRNAs encoding HIF-1α, VEGFA or VEGFR-2 (n =
d numbers of tubes per ﬁeld. ***p b 0.001, ###p b 0.001.
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pulmonary vascular hypertension associated with chronic hypoxia. Fi-
nally, the data suggest a role for this axis in further facilitating HPH by
increasing the expression of cellular adhesion molecules (CAMs, in
this case ICAM-1) which might promote inﬂammatory cellular inﬁltra-
tion and further facilitate remodelling.
We did not test however directly investigate whether blockade of
endogenous IL-33 signalling (though blockade either of IL-33 produc-
tion or blockade of ST2) reduces the hypoxia-induced proliferation of
these cells in the present study. However, we did ﬁnd that know
down of IL-33 gene using the siRNA technique attenuated hypoxia-
induced adhesion and tube formation by the HPAEC. We believe that
it is reasonable to speculate that blockade of IL-33/ST2 signalling in
HPAECmight exert a similar effect on proliferation of these cells because
this is presumably a feature of the hypoxia-induced, structural
reorganisation of these cells required for example for the formation of
tubules. This would be an interesting focus for our continuing experi-
ments in the future.
Not all existing studies in the literature suggest a detrimental role for
IL-33 in mediating haemodynamic changes. For instance, in a murine
model, administration of exogenous IL-33was reported to reduce aortic
atherosclerotic plaque formation and improve left ventricular function
[24]. In contrast, it has been shown that IL-33 induced expression of tis-
sue factor (TF) by human umbilical vein and coronary artery endothelial
cells, suggesting that may induce thrombosis around atherosclerotic
plaques in humans [25]. In addition, it has been shown that myocardial
pressure overload from hypertension can induce IL-33 production by
cardiovascular endothelial cells [26], which may induce local or even
systemic inﬂammation. Here, exposure of WT mice to hypoxia induced
obvious right, but not left ventricular hypertrophy as veriﬁed by alter-
ations in single cardiomyocyte diameter,while knockdown of St2 signif-
icantly abrogated this phenomenon, clearly implicating the IL-33/ST2
axis in the pathogenesis of HPH and consequent right heart failure.
There are already several studies in the literature implicating HIF-1α
and VEGF in the pathogenesis of the vascular remodellingwhich results
in HPH [1, 2]. Increased expression of HIF-1α has been noted in the
serum of patients with HPH and in the lungs in animal models [10]. De-
letion of the HIF-1α gene has previously been reported to down-
regulate VEGF signalling and abrogate haemodynamic changes in amu-
rine model of HPH [11]. Ours is however the ﬁrst study, to our knowl-
edge, implicating a mechanistic interaction between IL-33, HIF-1α and
VEGF in the pathogenesis of HPH.
It is known that structural cells of blood vessels such as smooth
muscle cells and ﬁbroblasts as well as endothelial cells can express IL-
33 [6, 21]. Demyanets et al. observed that the large vessels and cardiac
microvascular endothelial cells were the major sources expressing IL-
33 and ST2 [27], suggesting that, in vitro, exogenous human IL-33 acts
on vascular endothelial cells, but not cardiomyocytes, ﬁbroblasts or vas-
cular smooth muscle cells, at least in terms of eliciting production of
other proinﬂammatory cytokines. A very recent study has reported
that administration of IL-33 over a prolonged period results in the de-
velopment of pulmonary arterial hypertrophy [28]. Our data showed
that co-culture of vascular endothelial cells with smooth muscle cells
signiﬁcantly enhanced proliferation of the latter, an effect further en-
hanced in the presence of additional IL-33, while IL-33 alone exerted
no such effect. This suggests that additional, IL-33-enhanced mediators
derived from vascular endothelial cells may regulate smooth muscle
proliferation. It is also well known that many other cell types may ex-
press the IL-33 receptor ST2, including inﬂammatory cells such as
monocytes, raising the possibility that products of other adjacent struc-
tural cells activated through IL-33/ST2 may contribute to this
phenomenon.
To conclude, our experiments show that IL-33 and its receptor ST2
are constitutively expressed by human pulmonary arterial endothelial
cells and that hypoxia up regulates this expression. IL-33 acts on these
cells to enhance proliferation, adhesion and angiogenesis in an ST2-Please cite this article as: Liu J, et al, IL-33 Initiates Vascular Remodelling in
Expression in Vascular End..., EBioMedicine (2018), https://doi.org/10.101dependent fashion. These effects of IL-33/ST2, operating through activa-
tion of the HIF-1α/VEGF axis or otherwise, on pulmonary artery vascu-
lar endothelial cells may provide a basis for the initiation of vascular
smooth muscle cell, and possibly also cardiomyocyte remodelling
which eventually results in pulmonary hypertension, while hypoxia is
one potential initiator for up regulation of the IL-33/ST2 axis.Author Contributions
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